ADC Advances and Updated PARP Indications Support Focus on Individualized Approaches in Ovarian Cancer

Heather R. Williams, MD, expands on updated data from the the phase 3 PRIMA trial initially supporting the use of frontline PARP inhibitor maintenance in ovarian cancer, as well as changing indications for niraparib based on data from the NOVA trial.

Related Keywords

Arkansas ,United States ,Little Rock ,University Of Arkansas ,Heatherr Williams , ,Department Of Obstetrics ,Division Of Gynecologic Oncology ,Institutional Perspectives ,Gynecologic Oncology ,Medical Sciences ,Ovarian Cancer ,Ubamatamab ,Cemiplimab ,Recurrent Ovarian Cancer ,Uc16xcd3 Bispecific Antibody ,Phase 1 2 Study Nct03564340 ,